Ziprasidone in the Psychosis Prodrome
Conditions
Psychosis Prodrome
Trial Phase
Phase 2
Trial Purpose and Description
Trial Purpose
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Participation Guidelines
- Age:
- 16 Years - 40 Years
- Gender:
- Both
Eligibility Criteria
Inclusion Criteria:
- SIPS criteria for psychosis prodrome
- clinically referred
Exclusion Criteria:
- prolonged QTc
- history of syncope
- Sponsor:
- Yale University
- Dates:
- March 2008
- Last Updated:
- January 13, 2010
- Study HIC#:
- 0801003386
Clinicaltrials.gov ID: NCT00635700


